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Abstract: High blood pressure (BP) is the major cardiovascular risk factor and the main cause 
of death around the world. Control of blood pressure reduces the high mortality associated with 
hypertension and the most recent guidelines recommend reducing arterial BP values below 
140/90 mmHg for all hypertensive patients (130/80 in diabetics) as a necessary step to reduce 
global cardiovascular risk, which is the fundamental objective of the treatment. To achieve 
these target BP goals frequently requires combination therapy with two or more antihyper-
tensive agents. Although the combination of a diuretic and an angiotensin converting enzyme 
inhibitor (ACEI) is the most commonly used in the clinical practice, the combination of an 
ACEI and a calcium channel blocker may have an additive antihypertensive effect, a favorable 
effect on the metabolic proﬁ  le, and an increased target organ damage protection. The new oral 
ﬁ  xed combination manidipine 10 mg/delapril 30 mg has a greater antihypertensive effect than 
both components of the combination separately, and in non-responders to monotherapy with 
manidipine or delapril the average reduction of systolic and diastolic BP is 16/10 mmHg. The 
combination is well tolerated and the observed adverse effects are of the same nature as those 
observed in patients treated with the components as monotherapy. However, combination therapy 
reduces the incidence of ankle edema in patients treated with manidipine.
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Introduction
Arterial hypertension is a very common condition and the main cause of mortality 
in the world (Lopez et al 2006). Elevation of arterial blood pressures, even at levels 
that are considered clinically normal, is associated with an increase in cardiovascular 
diseases (ischemic heart disease, cerebrovascular disease, peripheral arteriopathy, 
and heart failure (Prospective Studies Collaboration 2002)). Furthermore, there is an 
accumulation of risk factors (dyslipidemia, hydrocarbonate intolerance/diabetes) and 
target organ damage (microalbuminuria, left ventricular hypertrophy) that increases 
cardiovascular risk and accounts for the high morbidity–mortality associated with 
hypertension in hypertensive patients (Guidelines Committee 2003). 
Antihypertensive treatment reduces 
cardiovascular events
Since the beginning of the 1970s, treatment of hypertension has been known to reduce 
associated mortality (VAC 1970). Many meta-analyses have demonstrated the superior-
ity of antihypertensive treatment versus placebo (BPLTT 2003, 2005). A controversy 
has existed for years regarding the superiority of some antihypertensive drugs over 
others, especially diuretics or beta-blockers versus calcium channel blockers (CCB), 
angiotensin converting enzyme inhibitors (ACEI), and angiotensin receptor blockers 
(ARB). However, a number of comparative studies have been published. From these 
we consider that the effect of the antihypertensive drugs, with some exceptions, is due Vascular Health and Risk Management 2007:3(3) 256
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more to the reduction of arterial pressures than to speciﬁ  c 
effects of the different antihypertensive groups (Guidelines 
Committee 2003). The prevailing opinion has been that the 
protective effect of all classes of drugs against cardiovascular 
mortality is the same, with equal degrees of blood pressure 
(BP) reduction.
Another very important aspect of treatment is that its 
beneﬁ  ts are achieved even though the number of patients 
with well-controlled BP is moderate in such studies (Mancia 
et al 2002). Furthermore, the importance of the reduction of 
arterial pressures has been demonstrated again recently. 
The VALUE (Valsartan Antihypertensive Long-Term 
Use Evaluation) study (Julius et al 2004) compared the ef-
fects of treatment based on valsartan (ARB) and amlodipine 
(CCB) on heart morbidity and mortality in high-risk hyper-
tensive patients. At study end (72 months) or ﬁ  nal visit the 
reductions in systolic BP (SBP) from baseline until study 
end were 15.2 mmHg and 17.3 mmHg in the valsartan and 
amlodipine groups, respectively. The difference between 
groups was substantial at 1 month (4.0 mmHg) but decreased 
to approximately 2.1 mmHg at 6 months and averaged 2.0 
mmHg thereafter. As with SBP, the difference in diastolic 
BP (DBP) between groups was substantial at 1 month (2.1 
mmHg) but decreased to 1.6 mmHg at 6 months and remained 
relatively constant thereafter. Targets of <140 mmHg SBP 
and <90 mmHg DBP were achieved in 56% of the valsartan 
group and 62% of the amlodipine group.
Although there was no signiﬁ  cant difference in the pri-
mary composite end point (cardiac morbidity or mortality) in 
these high-risk patients treated with valsartan- or amlodipine-
based regimens, a trend towards fewer fatal or non-fatal 
strokes in the amlodipine group was observed and there was 
a signiﬁ  cant decrease in the incidence of fatal and non-fatal 
myocardial infarction in the amlodipine group. However, 
as the study progressed and the differences in SBP became 
smaller, the odd ratios for myocardial infarction approached 
unity. Thus, unequal BP reductions might account for the 
reduced incidence of myocardial infarction and stroke seen 
with amlodipine, particularly early in the study when these 
differences were greatest.
Control of arterial blood pressure
The most recent European (Guidelines Committee 2003) 
and North American (Chobanian et al 2003) guidelines rec-
ommend reducing arterial BP values below 140/90 mmHg 
for all hypertensive patients over 18 years of age, including 
elderly patients, as long as it is tolerated clinically, as a 
necessary step to reduce global cardiovascular risk, which 
is the fundamental objective of the treatment. For high-risk 
hypertensive subjects, such as diabetics, those having silent 
lesions of the target organ or established cardiovascular clini-
cal disease, values below 130/80 mmHg should be reached 
and maintained. These should be even lower for patients with 
established kidney disease and nephrotic range proteinuria. 
In spite of such exact recommendations, control of 
hypertensive patients is very deﬁ  cient over almost all the 
world. Recent surveys in Europe have found an 18.7% rate 
of control in Germany in primary healthcare (Sharma et al 
2004). In specialized care in Italy, the care level that generally 
has the greatest control, control rate is 11.9% (Mancia et al 
2004). Rate of control was 42.1% in hospital-based hyper-
tension units in Spain (Banegas et al 2002). The percentage 
of control is much lower in diabetic patients. Control tends 
to be better in North America than in Europe: for European 
countries on average only 8% of hypertensive individuals 
have their condition well controlled compared with 23% in 
Canada and the United States (persons 35–64 years of age) 
(Wolf-Meier et al 2003). 
Different causes have been mentioned to explain 
poor control of arterial BP (Guidelines Committee 2003), 
including unknown or unsuspected secondary hypertension, 
limited treatment compliance, consumption of hypertensive 
substances or drugs, and failure to change life style (gaining 
weight or excessive drinking of alcohol). An important aspect 
to consider is that in spite of poor BP control, a signiﬁ  cant 
percentage of hypertensive patients receive antihypertensive 
monotherapy. Furthermore, among the patients uncontrolled 
with monotherapy, treatment is not modiﬁ  ed in most cases: 
for about three-quarters of visits in which elevated BP 
was recorded in treated hypertensives, physicians did not 
increase medications (Berlowitz et al 1998). Antihypertensive 
monotherapy leads to limited reduction in BP and manages 
to control only a moderate percentage of hypertensive sub-
jects. Many physicians do not prescribe enough medication 
to control their patients. 
In a recent meta-analysis (Law et al 2003) of 354 random-
ized, double-blind, placebo-controlled trials of the principal 
antihypertensive drugs, all categories of drug produced similar 
reductions in BP: 9.1 mmHg systolic and 5.5 mmHg diastolic 
at standard dose and 7.1 mmHg systolic and 4.4 mmHg dia-
stolic (20% lower) at half standard dose. The drugs reduced 
BP from all pretreatment levels, more so from higher levels. 
The BP-lowering effects of different categories of drugs were 
additive. An increase in the doses of thiazides, beta-blockers, 
and CCBs increased the rate of adverse effects; symptoms 
caused by ACEIs (mainly cough) were not dose related.Vascular Health and Risk Management 2007:3(3) 257
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Combination of drugs 
in the treatment of hypertension
To achieve target BP goals frequently requires combina-
tion therapy with two or more antihypertensive agents. The 
proportion of patients requiring combination therapy will 
depend on baseline BP values. In ALLHAT (ALLHAT 
2002), which recruited grade 1 and 2 hypertensives mostly 
on monotherapy, about 60% of the patients remained on 
monotherapy. In the HOT study (Hanson et al 1998), which 
recruited grade 2 and 3 hypertensives after washout from 
previous medication, monotherapy was successful in only 
25%–40% of patients, according to the target DBP.
Since most hypertensive patients will require two or more 
antihypertensive medications to achieve their BP goals, the 
2003 European Society of Hypertension/European Society of 
Cardiology guidelines (Guidelines Committee 2003) consider 
reasonable initiating therapy either with a low dose of a single 
agent or with a low dose combination of two agents. To initi-
ate therapy with a combination of two drugs with different 
mechanisms of action increases the possibility that BP and its 
complications are controlled, and because ﬁ  xed low-dose com-
binations are available the administration of two agents within 
a single tablet is possible, thus optimizing compliance. The 
seventh Report of the Joint National Committee (Chobanian 
et al 2003) recommends the addition of a second drug from a 
different class when use of a single agent in adequate doses 
fails to achieve the goal. In addition when BP is >20 mmHg 
above SBP goal or 10 mmHg above DBP goal, consideration 
should be given to initiating therapy with two drugs, either as 
separate prescriptions or in ﬁ  xed-dose combinations. 
The initiation of therapy with more than one drug increases 
the likelihood of achieving the BP goal early. The use of 
multidrug combinations often produces greater BP reduction 
at lower doses of the component agents, resulting in fewer 
side-effects. The use of ﬁ  xed-dose combinations may be more 
convenient and simplify the treatment regimen, and may cost 
less than the individual components prescribed separately.
Diuretic therapy is the logical add-on therapy following 
optimization of ACEI or ARB. The available evidence suggests 
that long-acting CCBs remain a logical, safe, and very effective 
addition, as recommended in the ESH/ESC guidelines.
Combination of renin-angiotensin 
system blockade and CCB therapy
Angiotensin renin system inhibition, with both ACEIs and 
ARBs, plays a fundamental role in the antihypertensive treat-
ment. Although it is still unknown what role angiotensin II plays 
in the maintenance of high BPs in the hypertensive subject, its 
involvement in the physiopathology of target organ damage and 
in the main complications of hypertension is clear. 
ACEIs reduce BP by reducing the circulating levels 
of angiotensin II. Although the role of the tissue renin–
angiotensin system in pathophysiology remains unclear 
ACEIs  inhibit ACE activity within the vessel wall and 
multiple tissues such as heart and brain.
The ACEIs reduce left ventricular hypertrophy more 
than other antihypertensive drugs (Klingbeil et al 2003). 
This is probably partly due to their effect on the cardiac 
renin-angiotensin system (RAS), but they also increase 
distensibility of the aorta and reduce the reﬂ  ected arterial 
wave amplitude (London et al 1996). They reduce wall 
remodeling in the small resistance arteries, reducing the 
media thickness and media width to lumen ratio (Schiffrin 
et al 1994).
In the kidney, the ACEIs decrease constriction of the 
efferent arteriole induced by angiotensin II, reducing intra-
glomerular pressure and protecting the kidney, especially in 
hypertensive or normotensive diabetic subjects. They reduce 
morbidity–mortality and slow down progression toward renal 
failure in type 1 diabetics (Lewis et al 1993). They also reduce 
urinary excretion of albumin and progression of nephropathy 
with proteinuria (Jafar et al 2001). Administration of 
ACEI compared with placebo reduced the incidence of 
microalbuminuria in normoalbuminuric type 2 diabetic 
subjects (Ruggeneti et al 2005).
Furthermore, the ACEIs have been shown to reduce 
insulin resistance associated with arterial hypertension and 
reduce the incidence of diabetes mellitus in long-duration 
studies compared with other classes of antihypertensive drugs 
(Mancia et al 2006). 
CCBs are a group of antihypertensive agents consti-
tuted by 3 families: benzothiazepine (diltiazem), phenyl-
alkylamine (verapamil), which are heart rate slowing, and 
dihydropiridines, which are predominantly vasodilators. 
Their mechanism of action is that of reducing cytosolic 
calcium content of the smooth muscle cells of the vessels, 
reducing their contraction and vasodilating the small arter-
ies. CCBs block Ca entry through Ca channels. They block 
L type calcium channels (Pitt B 1997)
These are excellent antihypertensive agents. Their 
primary action is to block Ca entry through Ca channels, and 
they also restore nitric oxide availability (Taddei et al 2001) 
and tend to be more effective at high rather than low sodium 
intake (Luque Otero et al 1987), perhaps because they have 
a natriuretic effect. Their antihypertensive beneﬁ  t is well Vascular Health and Risk Management 2007:3(3) 258
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documented in the elderly, and in the presence of isolated 
systolic hypertension (Liu et al 1998).
CCBs reduce left ventricular hypertrophy, practically 
in the same way as the ACEIs (Klingbeil et al 2003). Their 
renal effects are controversial, perhaps because their vasodila-
tor effect is limited to the afferent arteriole, and they tend to 
increase intraglomerular pressure (Zanchi et al 1995) that could 
eventually be associated with the progression of renal disease 
(Grifﬁ  n et al 1995). In type 2 diabetics the dihydropyridine 
CCBs tend to have a neutral or adverse effect on proteinuria, 
whereas the non-dihydropyridine CCBs tend to reduce the rise 
in proteinuria. But these studies are really too small to enable 
deﬁ  nitive clinical conclusions to be drawn (Kloke et al 1998)
In contrast to the predominant action on the afferent 
arterioles of conventional types of CCB, the novel molecules 
such as manidipine acting on both afferent and efferent 
arterioles may correct glomerular hypertension, reduce mi-
croalbuminuria, and prevent the progression of renal disease 
(Tojo et al 1992).
Both in animal as well as human models, the CCBs 
reduce progression of arteriosclerosis plaques (Simon et al 
2002). This has been demonstrated in comparative follow-
up studies with other antihypertensive agents (Zanchetti 
et al 1998, 2002).
The combination of ACEIs and CCB is greatly used in 
clinical practice because both drug groups have different 
mechanisms of action that may be complementary. Table 1 
shows the possible beneﬁ  ts of the combination of both drugs 
(Swales et al 2002).  
Fixed dose combination of ACEI–CCB therapy was 
shown to be equally efﬁ  cacious as ACEI–thiazide (Letellier 
et al 1994) or β-blocker–diuretic combinations (De Leuw 
et al 1997). However, the results of the Anglo-Scandinavian 
Cardiac Outcomes Trial-Blood Pressure Lowering Arm 
(ASCOT) Study demonstrated that among 19,257 high risk 
hypertensives, treatment with the amlodipine–perindopril 
combination (if necessary to achieve the target BP) prevented 
more major cardiovascular events and induced less diabetes 
than treatment with the atenolol–thiazide combination 
(if necessary), suggesting a superiority of the combined 
treatment with ACEI–CCB over betablocker–thiazide. The 
study was stopped prematurely after 5·5 years’ median 
follow-up because compared with those allocated to the 
amlodipine-based regimen the patients allocated to the 
atenolol-based regimen had signiﬁ  cantly higher mortality as 
well as worse outcomes on several other secondary endpoints: 
fatal and non-fatal stroke (327 vs 422; 0.77, 0.66–0.89, 
p = 0.0003), total cardiovascular events and procedures (1362 
vs 1602; 0.84, 0.78–0.90, p < 0.0001), and all-cause mortality 
(738 vs 820; 0.89, 0.81–0.99, p = 0.025). The incidence of 
developing diabetes was less on the amlodipine-based regi-
men (567 vs 799; 0.70, 0.63–0.78, p < 0.0001). As occurred 
in the VALUE trial, compared with those allocated the ateno-
lol–thiazide-based regimen, BP values were lower throughout 
the trial in those allocated the amlodipine–perindopril-based 
regimen. These differences were largest (5.9/2.4 mmHg) at 
3 months, and the average difference throughout the trial 
was 2.7/1.9 mmHg. The higher BP lowering achieved in the 
amlodipine–perindopril group, particularly in the ﬁ  rst year 
of follow-up, is likely to have contributed to the differential 
cardiovascular beneﬁ  ts (Dahlof et al 2005)
Manidipine
Manidipine is a third-generation CCB with a long dura-
tion of action because of its high lipophilic nature, strong 
membrane binding, and slow release to calcium channels. 
Manidipine inhibits the calcium inﬂ  ux to the cell by antago-
nism on calcium channels (Okabe et al 1987). In addition, 
and in contrast with other CCBs, manidipine not only blocks 
the L-type calcium channels but also the T-type channels 
(Furukawa 2005) that are distributed in the sinoatrial node 
and participate in the pathogenesis of cardiac hypertrophy 
and in cardiac remodeling
Manidipine is highly selective for the vasculature. Its 
antihypertensive effects have been well documented in 
clinical studies (McKeage and Scott 2004) and result from 
peripheral vasodilation without any signiﬁ  cant modiﬁ  cation 
of norepinephrine levels, suggesting a lack of sympathetic 
activation (Fogari et al 2000). Manidipine reduced BP in a 
dose-dependent manner between 10 and 40 mg daily and the 
usual dosage in clinical practice is established at between 10 
and 20 mg daily. The antihypertensive effect of once-daily 
manidipine administration is maintained during the 24-hour 
period without disturbing the circadian BP rhythm (Fogari et 
al 1996). Manidipine has been compared with other CCBs 
such as amlodipine, felodipine, lercanidipine, and nifedipine 
Table 1 Possible beneﬁ  ts of the combination of calcium channel 
blockers and angiotensin converting enzyme inhibitors (adapted 
from Swales and Williams 2002)
More effective reduction in stroke
Reduction of left ventricular mass
Control of ventricular dysrhythmias
To improve cardiac ﬁ  lling and contractility 
More effective prevention (and regression) of atherogenesis 
Additional possible antiproteinuric effects
More favorable effects on the metabolic proﬁ  le Vascular Health and Risk Management 2007:3(3) 259
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(McKeage and Scott 2004), its antihypertensive effect being 
of a similar magnitude and dose-related. In contrast, fewer 
manidipine-treated patients experienced ankle edema than 
patients treated with amlodipine (Zanchetti et al 2001), per-
haps reﬂ  ecting a lesser activation of the sympathetic nervous 
system (Fogari 2005). There were no clinically relevant ef-
fects on heart rate with recommended dosages of manidipine 
(10 or 20 mg once daily). 
Long-term treatment with manidipine significantly 
reduced the left ventricular mass index in hypertensive 
patients with type 2 diabetes and microalbuminuria. After 
2 years’ treatment, manidipine produced a greater reduction 
of left ventricular mass index than lisinopril (14.9 g/m2 vs 
–10.8 g/m2 at 24 months) (Fogari et al 2005).
Unlike the conventional types of CCB, manidipine dilates 
both efferent and afferent arterioles in animal models (Hayasi 
et al 1996) thus reducing intraglomerular pressure. In hyper-
tensive patients with microalbuminuria and type 2 diabetes, 
manidipine 10 or 20 mg once daily effectively lowered BP 
from baseline as well as ACEIs such as enalapril (Mancia et al 
200; Luque et al 2005) or lisinopril. Manidipine and lisinopril 
signiﬁ  cantly decreased albumin excretion rate (AER), but it 
was slightly but signiﬁ  cantly more pronounced with lisinopril 
(at 24 weeks, –37.2 mg/24 hours, p < 0.001 vs baseline) than 
with manidipine (–29.9 mg/24 hours, p < 0.05 vs baseline) 
(Fogari et al 2005). In hypertensive type 2 diabetics with 
microalbuminuria and uncontrolled BP treated with ARBs or 
ACEIs, the addition of manidipine to the treatment caused a 
large reduction in both blood pressure (–18/6.5 mmHg) and 
AER (–60%). Over one third of the patients reached the AER 
target (<20 mg/min) (Martinez et al 2004).
Moreover, manidipine improved insulin resistance as 
assessed by glucose clamp technique in essential hyperten-
sives (Iimura et al 1995) and in hypertensive type 2 diabetics 
(Suzuki et al 1996). 
Delapril
Delapril is a non-sulfhydryl ACEI. It is an esteriﬁ  ed pro-drug 
that is converted in vivo to its active metabolites — delapril 
diacid and 5-hydroxy delapril diacid. The vast body of 
evidence collected by various studies shows that delapril, 
at doses between 30 and 120 mg/day, is endowed with a 
signiﬁ  cant antihypertensive effect (Onayama et al 1988). 
Once-daily administration of delapril maintains the antihy-
pertensive action for 24 hours (Fogari et al 1997). Delapril is 
eliminated mainly through urine and in patients with marked 
renal impairment there is a need for dosage adjustment 
(Onoyama et al 1988).
The antihypertensive effect of delapril is similar that 
the obtained with other ACEIs and has renoprotective and 
cardioprotective actions, with a lower incidence of cough 
than captopril or enalapril (Saruta and Nishikawa 1991). 
Delapril increased the insulin sensitivity in hypertensive type 
2 diabetic patients (Suzuki et al 1996).
Manidipine–delapril
Pharmacokinetic studies of the combination demonstrated 
that co-administration of single oral doses of manidipine 
10 mg and delapril 30 mg in healthy volunteers did not 
modify the pharmacokinetics of either drug or those of their 
major metabolites (Stockis et al 2003).
Antihypertensive efﬁ  cacy
Dose ﬁ  nding
The optimum dosage of each component of the combina-
tion was determined in a study using a 3 × 3 factorial design 
combining manidipine 5 or 10 mg, delapril 15 or 30 mg, or 
placebo administered once daily during 6 weeks. The study 
was randomized, double-blind, and 400 patients with mild to 
moderate hypertension were randomized. The most effective 
combination was 30 mg delapril and 10 mg manidipine once 
daily. The reduction of BP from baseline was 15/13 mmHg for 
SBP and DBP, respectively. The placebo-corrected reduction 
of BP, 11/9 mmHg, resulted in a good control of BP in 72% 
of the patients (Ambrosioni 1998; Bachelli et al 2002).
Comparison with the components in monotherapy
The antihypertensive efficacy of the fixed combination 
manidipine 10 mg/delapril 30 mg is higher than the efﬁ  cacy 
of its components administered in monotherapy, as was dem-
onstrated in a randomized, double-blind study in essential 
hypertensives treated for 12 weeks with manidipine (134 
patients), delapril (136 patients), and the ﬁ  xed-combination 
(131). At the end of the study the mean reduction of DBP 
from baseline in the trough was 14 mmHg in the group treated 
with combination therapy, signiﬁ  cantly higher than with 
delapril (10 mmHg, p < 0.001) or manidipine (11 mmHg, 
p < 0.05) alone. The reductions of SBP were also greater 
with the ﬁ  xed combination (19 mmHg) than with delapril 
(14 mmHg, p < 0.01) or manidipine (15 mmHg, p < 0.05) 
monotherapy. At the end of the study 76% of the patients 
treated with the ﬁ  xed combination of manidipine–delapril had 
DBP <90 mmHg, and 71% SBP <140 mmHg. The respective 
proportions for patients treated with delapril or manidipine 
alone were 57% and 54%, and 64% and 49% respectively 
(Zannad 2004).Vascular Health and Risk Management 2007:3(3) 260
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Efﬁ  cacy in non-responders to monotherapy with the 
components 
The antihypertensive efﬁ  cacy of the ﬁ  xed combination mani-
dipine 10 mg/delapril 30 mg once daily in non-responders to 
monotherapy with either component was assessed in an open 
label phase III study in patients with moderate hypertension. 
The patients were included in the study if their DBP was >90 
mmHg (95% of the patients) or they experienced adverse 
events (5% of the patients) with either manidipine 20 mg od 
(n = 152) or delapril 30 mg twice daily. After 12 weeks of 
follow-up the mean reductions from baseline in sitting SBP 
and DBP were 16/10.1 mmHg in the group previously treated 
with manidipine, and 15.8/11 mmHg in the non-responders 
to delapril; both reductions were statistically signiﬁ  cant. The 
rate of normalized DBP (90 mmHg) and responder rate 
(DBP reduction 10 mmHg) was 79% in the patients previ-
ously treated with manidipine and 82% in non-responders to 
delapril (Zoppi et al 2003).
Evaluation of antihypertensive action by 24-hour 
ambulatory BP monitoring
The ﬁ  xed combination of manidipine–delapril produced 
signiﬁ  cant and smooth reductions in BP values, which per-
sisted during the 24-hour interval. This was demonstrated 
in essential hypertensives inadequately controlled by mono-
therapy with either component who were treated with the 
ﬁ  xed combination for 8 weeks. A 24-hour ambulatory BP 
monitoring recording was performed before and at the end 
of the combination therapy. BP control over 24 hours was 
quantiﬁ  ed by the trough-to-peak ratio and the smoothness 
index. Compared with placebo, the ﬁ  xed combination of 
manidipine and delapril produced a statistically signiﬁ  cant 
(p < 0.01) decrease in sitting clinic (18/14 mmHg) and 
24-hour blood pressure (12/10 mmHg) without affecting 
heart rate. At the end of the 8-week combination treatment 
period, the rate of normalized patients was 73%. Treatment 
with the ﬁ  xed combination was associated with a positively 
high smoothness index and with a relatively good trough-to-
peak ratio (0.46/0.60). These results support the use of ﬁ  xed 
manidipine–delapril combination in the treatment of mild to 
moderate hypertensive patients inadequately controlled by 
monotherapy (Mugellini et al 2005).
Comparison with other combinations 
of antihypertensive drugs
To compare the antihypertensive efﬁ  cacy of the ﬁ  xed com-
bination manidipine 10 mg/delapril 30 mg with the stan-
dard combination of an ACEI and a diuretic, hypertensive 
patients were randomized in a 2:1 ratio after a 2-week 
single-blind placebo to receive delapril 30 mg (n = 106) or 
enalapril 20 mg (n = 54) during 8 weeks. Non-responders 
(sitting DBP 85 mmHg) received delapril 30 mg plus 
manidipine 10 mg or enalapril 20 mg plus hydrochlorothia-
zide (HCTZ) 12.5 mg once daily for an additional 8-week 
period. After 16 weeks the mean reduction of DBP was 
similar with the two treatments (delapril –14, enalapril –15 
mmHg) with no differences between manidipine–delapril 
and enalapril–HCTZ treatments. More than 50% of the 
patients in both groups had their DBP controlled (Mugellini 
et al 2004a). 
The efﬁ  cacy of the combination manidipine–delapril was 
compared with the irbesartan–HCTZ combination in 80 mild 
to moderate hypertensives with concomitant type 2 diabe-
tes. After an initial 4-week period on placebo patients were 
randomly assigned to receive delapril 30 mg or irbesartan 
150 mg once daily for 8 weeks. Thereafter, manidipine 10 
mg was added to delapril and HCTZ 12.5 mg as added to 
irbesartan for a further 8 weeks. Both delapril and irbesar-
tan signiﬁ  cantly reduced SBP and DBP and no differences 
in BP-lowering efﬁ  cacy was found either between the two 
monotherapies (delapril: from 161/101 mmHg at baseline 
to 146/90 mmHg; irbesartan: from 160/100 at baseline to 
144/89 mmHg) or between the two combination therapies 
(BP at the end of the 8 weeks follow-up 134/80 mmHg in 
both groups). There were no signiﬁ  cant changes in fasting 
blood glucose and plasma insulin, and the diabetic control 
as assessed by HbA1c concentration was not inﬂ  uenced by 
both treatments. The manidipine–delapril combination gave a 
greater improvement in ﬁ  brinolytic function, greater decrease 
in PAI-I activity, and greater increase in t-PA activity, while 
the irbesartan–HCTZ combination gave a worse ﬁ  brinolytic 
function (Mugellini et al 2004b). 
Two other studies have been presented as abstracts. One 
compared the BP-lowering effects of the manidipine–delapril 
combination with that of ramipril–HCTZ or valsartan–HCTZ 
in hypertensive type 2 diabetic patients. Patients were ﬁ  rst 
randomized to receive delapril 30 mg, ramipril 2.5 mg, or 
valsartan 80 mg during 6 weeks. Those patients with DBP 
>90 mmHg after 6 weeks of treatment received a second 
drug: manidipine 30 mg in those treated with delapril, 
HCTZ 12.5 mg in those treated with either ramipril or 
valsartan, for an additional 44 weeks. The mean decrease 
of BP was similar in the three groups, as was the proportion 
of patients controlled. The conclusion of the study was that 
the BP lowering of the three combinations tested was similar 
(Rizzoni et al 2005). The other study (Trimarco et al 2005) Vascular Health and Risk Management 2007:3(3) 261
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included patients not controlled in monotherapy randomized 
to receive the combination delapril 30 mg/manidipine 10 mg 
or lisinopril 20 mg/HCTZ 12.5 mg for 12 weeks. BP was 
reduced signiﬁ  cantly with both treatments (manidipine–del-
april: –21.5/–15.7 mmHg, lisinopril–HCTZ: –23.8/–16.2 
mmHg) and the percentage of patients with BP <140 and 
90 mmHg was slightly higher, although non signiﬁ  cantly, 
in patients treated with manidipine–delapril than in those 
treated with lisinopril–HCTZ (60% vs 54%). 
Log-term administration of the combination
The long-term effects of the treatment with the ﬁ  xed com-
bination manidipine 10 mg/delapril 30 mg was assessed in 
a multicenter non-comparative follow-up study of 309 mild 
to moderate hypertensives. Patients with DBP >95 mmHg 
after 4 weeks of treatment with the ﬁ  xed combination were 
given additional therapy with HCTZ 12.5 mg. The antihy-
pertensive efﬁ  cacy of the ﬁ  xed combination was maintained 
during the 50 weeks of follow up. BP reduction from baseline 
after  4 weeks of treatment was –16.6/–9.3, and at the end of 
the study the BP reduction reached –21.8/–14.3 mmHg. The 
percentage of patients with DBP 90 mmHg was 80.6% and 
the rate of patients with both SBP and DBP 140 and 90 
mmHg was 55.3% (Karpati et al 2003). 
Tolerability
Tolerability of the ﬁ  xed combination manidipine 10 mg/
delapril 30 mg has been assessed in the clinical studies 
previously reviewed. In the long-term study, after 50 weeks 
of follow up (Karpati et al 2003) 43.4% of the patients re-
ported adverse events but only 14.2% seemed to be related to 
therapy. The most frequently reported adverse event among 
the 263 patients allocated to the combination manidipine 10 
mg/delapril 30 mg was cough (2.7%) and the second was 
ankle edema (1.9%). Fifteen patients withdrew from the 
study due to adverse events. 
Compared with other combinations of drugs manidip-
ine–delapril has a similar incidence of adverse events to 
lisinopril–HCTZ (Trimarco et al 2005), enalapril–HCTZ 
(Mugellini et al 2004), ramipril–HCTZ, and valsartan–HCTZ 
(Rizzoni et al 2005). 
In the phase III studies the tolerability of the ﬁ  xed combi-
nation was similar to that the observed with its components 
in monotherapy (Zannad 2004). In a study published as an 
abstract (Fogari et al 2003) monotherapy with manidipine 
elevated pretibial subcutaneous tissue pressure and ankle-foot 
volume. But after treatment with the combination manidip-
ine 10 mg/delapril 30 mg once daily, the increases in these 
measures of ankle edema were signiﬁ  cantly less than those 
with manidipine alone.
In all the studies there were no signiﬁ  cant changes in bio-
chemical and metabolic parameters in the patients receiving 
the ﬁ  xed combination of manidipine 10 mg/delapril 20 mg
Concluding comments
Control of BP is a very important objective in reducing 
the high morbidity and mortality observed in hypertensive 
patients. Current guidelines recommend achieving goal 
BPs below those acceptable in the past. Thus combina-
tion therapy is required to achieve BP targets in a large 
proportion of patients with hypertension. Moreover, the 
current international guidelines for the management of 
hypertensive patients recommend these combinations for 
ﬁ  rst-line treatment.
The combination of a CCB with an ACEI has been shown 
to have an additive antihypertensive effect because every 
drug lowered BP by different mechanism, both reducing 
peripheral resistance with little effects on cardiac output. In 
addition to the favorable effects of each of its components on 
target organ damage, this combination has been shown to be 
superior in terms of morbidity and mortality to the classical 
combination of diuretics and beta-blockers.
The ﬁ  xed combination of delapril 30 mg/manidipine 10 
mg is an effective and well tolerated antihypertensive therapy, 
increasing the BP decrease in patients with poor response to 
delapril or manidipine monotherapy. Its effect was similar to 
the effects obtained with other ﬁ  xed combinations of ACEIs 
or ARBs with diuretics. 
References 
Banegas JR, Segura J, Ruilope LM, et al. 2004. Blood pressure control and 
physician management of hypertension in hospital hypertension units 
in Spain. Hypertension, 43:1338–44.
Bachelli S, Degli Espositi D, Alberici M, et al. 2002. Effects of the com-
bination of different doses of manidipine and delapril in hypertesive 
patients. Am J Hypertens, 15:45–6A.
Berlowitz DR, Ash AS, Hickey EC, et al. 1998. Inadequate manage-
ment of blood pressure in a hypertensive population. N Engl J Med, 
339:1957–63.
[BPLTT] Blood Pressure Lowering Treatment Trialists’ Collaboration. 
2003. Effects of different blood-pressure-lowering regimens on major 
cardiovascular events: results of prospectively-designed. overviews of 
randomised trials. Lancet, 362:1527–35.
[BPLTT] Blood Pressure Lowering Treatment Trialists’ Collaboration. 
2005. Effects of different blood pressure-lowering regimens on major 
cardiovascular events in individuals with and without diabetes mellitus: 
results of prospectively designed overviews of randomized trials. Arch 
Intern Med, 165:1410–19.
Chobanian AV, Bakris G, Black H, et al. 2003. The Seventh Report of 
the Joint National Committee on Prevention, Detection, Evaluation 
and Treatment of High Blood Pressure: The JNC 7 Report. JAMA, 
289:2560–72.Vascular Health and Risk Management 2007:3(3) 262
Luque Otero
Dahlöf B, Sever PS, Poulter NR, et al. 2005. Prevention of cardiovascular 
events with an antihypertensive regimen of amlodipine adding per-
indopril as required versus atenolol adding bendroﬂ  umethiazide as 
required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized 
controlled trial. Lancet, 366:895–906.
De Leeuw PW, Kroon AA. 1997. Fixed low-dose combination of an 
angiotensin converting enzyme inhibitor and a calcium channel blocker 
drug in the treatment of essential hypertension. J Hypertens, 15(Suppl 
2):39–42.
Fogari R, Zoppi A, Lusardi P, et al. 1996. Evaluation by 24-hour ambula-
tory blood pressure monitoring of efﬁ  cacy of manidipine hydrochloride 
10, 20 or 40 mg once daily ascompared to placebo in treating mild to 
moderate essential hypertension: a double-blind, randomized, parallel 
group, placebo-controlled study. Blood Press, 5(Suppl 5):16–23.
Fogari R, Zoppi A, Mugellini A, et al. 1997. Efﬁ  cacy of delapril in the treat-
ment of mild to moderate essential hypertension: evaluation by 24-hour 
ambulatory blood pressure monitoring. Adv Ther, 14:254–61.
Fogari R, Zoppi A, Corradi L, et al. 2000. Effects of different dihydropiridine 
calcium antagonists on plasma norepinephrine in essential hypertension. 
J Hypertens, 18:1871–5.
Fogari R, Malamani G, Derosa G, et al. 2003. Effect of delapril addition 
to manidipine on ankle oedema and subcutaneous tissue pressure in 
hypertensive patients [abstract no. P-205]. Am J Hypertens, 16:113A.
Fogari R. 2005. Ankle edema and sympathetic activation. Drugs, 65(Suppl 
2):21–7.
Fogari R, Mugellini A, Zoppi A, et al. 2005. Effect of successful hyperten-
sion control by manidipine or lisinopril on albuminuria and left ven-
tricular mass in diabetic hypertensive patients with microalbuminuria. 
Eur J Clin Pharmacol, 61:483–90.
Furukawa T, Nukada T, Miura R, et al. 2005. Differential blocking action of 
dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) 
expressed in Xenopus oocytes. J Cardiovasc Pharmacol, 45:241–6.
Grifﬁ  n KA, Picken MM, Bidani AK. 1995. Deleterious effects of calcium 
channel blockers on pressures transmissions and glomerular injury in 
rat remmant kidneys. J Clin Invest, 96:793–800.
Guidelines Committee. 2003. European Society of Hypertension–European 
Society of Cardiology Guidelines for the Management of Arterial 
Hypertension. J Hypertens, 21:1011–53.
Hansson L, Zanchetti A, Carruthers SG et al. 1998. Effects of intensive 
blood pressure lowering and low-dose aspirin in patients with hyperten-
sion: principal results of the Hypertension Optimal Treatment (HOT) 
randomised trial. Lancet, 351:1755–62.
Hayasi K, Nagahama T, Oka K, et al. 1996. Disparate effects of calcium 
antagonists on renal microcirculation. Hypertens Res,19:31–6.
Iimura O, Shimamoto K, Masuda A, et al. 1995. Effects of a calcium channel 
blocker, manidipine, on insulin sensitivity in essential hypertensives. 
J Diab Camp, 9:215–19.
Jafar TH, Schmid CH, Landa M, et al. 2001Angiotensin converting enzyme 
inhibitors and progression of nondiabetic renal disease. Ann Intern 
Med, 135:733–87.
Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hyperten-
sive patients at high cardiovascular risk treated with valsartan- or 
amlodipine-based regimens: VALUE, a randomised trial. Lancet, 
363:2022–31.
Karpati P, Alberici M, Tocci G, et al. 2003. Long-term tolerability and efﬁ  -
cacy of the ﬁ  xed combination of manidipine and delapril in patients with 
essential hypertension. High Blood Press Cardiovasc Prev, 10:1–6.
Klingbeil AU, Schneider M, Martus P et al. 2003. A meta-analysis of the 
effect of treatment of left ventricular mass in essential hypertension. 
Am J Med, 115:41–6.
Kloke HJ, Branten AJ, Huysmans FT, et al. 1998. Antihypertensive treatment 
of patients with proteinuric renal diseases: risks or beneﬁ  ts of calcium 
channel blockers? Kidney Int, 53:1559–73.
Law MR, Wald NJ, Morris JK, et al. 2003. Value of low dose combina-
tion treatment with blood pressure lowering drugs: analysis of 354 
randomised trials. BMJ,326:1407–8.
Letellier P, Overlack A, Agnes E. 1994. Perindopril plus nifedipine versus 
perindopril plus hydrochlorothiazide in mild to severe hypertension: a 
double-blind multicentre study. The Multicentre Study Group on Treat-
ment Association with Perindopril. J Hum Hypertens, 8:145–9.
Lewis EJ, Hunsicker LG, Bain RP, et al. 1993. The effect of angiotensin-
converting-enzyme inhibition on diabetic nephropathy. The Collabora-
tive Study Group. N Engl J Med, 329:1456–62.
London GM, Pannier B, Vicaut E, et al. 1996. Antihypertensive effects and 
arterial hemodynamic alterations during angiotensin converting enzyme 
inhibition. J Hypertens, 14:1139–46.
Lopez A, Mathers CD, Ezzati M, et al. 2006. Global and regional burden of 
disease and risk factors, 2001: systematic analysis of population health 
data. Lancet, 367:1747–57.
Liu L, Wang JG, Gong L, et al. 1998. Comparison of active treatment and 
placebo for older Chinese patients with isolated systolic hypertension. 
J Hypertens, 16:1823–9.
Luque Otero M, Fernández Pinilla C, Catalán P, et al 1987. Acute antihy-
pertensives effect of nifedipine on high and low salt diet. J Cardiovasc 
Pharmacol, 10 (Suppl 10):S147–8.
Luque Otero M, Martell Claros N, on behalf of the Study Investigators 
Group. 2005. Manidipine versus enalapril monotherapy in patients with 
hypertension and type 2 diabetes mellitus: a multicenter, randomized, 
double-blind, 24-week study. Clin Ther, 27:166–73. 
Mancia G, Omboni S, Agabiti-Rosei E, et al. 2000. Antihypertensive 
efﬁ  cacy of manidipine and enalapril in hypertensive diabetic patients. 
J Cardiovasc Pharmacol, 35:926–31.
Mancia G, Grassi G. 2002. Systolic and diastolic blood pressure control in 
antihypertensive trials. J Hypertens, 20:1461–4.
Mancia G, Volpe R, Boros S, et al. 2004. Cardiovascular risk proﬁ  le and 
blood pressure control in Italian hypertensive patients under specialist 
care. J Hypertens, 22:51–7.
Mancia G, Grassi G, Zanchetti A. 2006. New-onset diabetes and antihyper-
tensive drugs. J Hypertens, 24:3–10.
Martinez-Martin FJ, Saiz-Satjes M. 2004. Addition of manidipine in type 2 
diabetic patients with uncontrolled hypertension and microalbuminuria. 
J Hypertens, 22(Suppl 2):s245.
McKeage K, Scott LJ. 2004. Manidipine: a review of its use in the manage-
ment of hypertension. Drugs, 64:1923–40.
Mugellini A, Dobovisek J, Planinc D, et al. 2004. Efﬁ  cacy and safety of 
delapril plus manidipine compared with enalapril plus hydrochlorothia-
zide in mild to moderate essential hypertension: results of a randomized 
trial. Clin Ther, 26:1419–26.
Mugellini A, Preti P, Zoppi A, et al. 2004. Effect of delapril -manidipine 
combination vs irbesartan-hydrochlorothiazide combination on ﬁ  bri-
nolytic function in hypertensive patients with type II diabetes mellitus. 
J Hum Hypertens, 18:687–91 
Mugellini A, Vaccarella A, Celentano A, et al. 2005. Fixed combination of 
manidipine and delapril in the treatment of mild to moderate essential 
hypertension: evaluation by 24-hour ambulatory blood pressure moni-
toring. Blood Pressure, 14(Suppl 1):6–13.
Okabe K, Terada K, Kitamura K, et al. 1987. Selective and long lasting 
inhibitory actions of the dihydropyridine derivative, CV-4093, on cal-
cium currents in smooth muscle cells of the rabbit pulmonary artery. 
J Pharmacol Exp Ther, 243:703–10.
Onoyama K, Nanishi F, Okuda S, et al. 1988. Pharmacokinetics of a new 
angiotensin I converting enzyme inhibitor (delapril) in patients with 
deteriorated kidney function and in normal control subjects. Clin 
Pharmacol Ther, 43:242–9.
Pitt B. 1997. Diversity of calcium antagonists. Clin Ther, 19(Suppl 
A):3–17.
Prospective Studies Collaboration. 2002. Age-speciﬁ  c relevance of usual 
blood pressure to vascular mortality: a meta-analysis of individual data 
for one million adults in 61 prospective studies. Lancet, 360:1903.
Rizzoni D, Bevilacqua M, Gobbato C, et al. 2005. Blood pressure lowering 
effects of delapril and manidipine, in hypertensive patients with type 
2 diabetes, not adequately controlled by monotherapy [abstract]. High 
Blood Press Cardiovasc Prev, 12:180(abstract no. 8.6).Vascular Health and Risk Management 2007:3(3) 263
Manidipine–delapril in hypertension
Ruggenenti P, Fassi A, Ilieva AP, et al, for the Bergamo Nephrologic 
DIabetes Complications Trial (BENEDICT) Investigators. 2004. 
preventing microalbuminuria in type 2 diabetes. N Engl J Med, 
351:1941–51.
Saruta T, Nishikawa K. 1991. Characteristics of a new angiotensin convert-
ing enzyme inhibitor: delapril. Am J Hypertens, 4:23S–28S.
Schiffrin EL, Deng LY, Larochelle P. 1994. Effects of a beta-blocker or a 
converting enzyme inhibitor on resistance arteries in essential hyperten-
sion. Hypertension, 23:83–91.
Sharma A, Wittchen H-U, Kirch W, et al, for the HYDRA Study Group. 
2004. High prevalence and poor control of hypertension in primary 
care: cross-sectional study. J Hypertens, 22:479–86.
Simon A, Gariepy J, Chironi G, et al. 2002. Intima-media thickness: a new 
tool for diagnosis and treatment of cardiovascular risk. J Hypertens, 
20:159–70.
Stockis A, Gengler C, Goethals F, et al. 2003. Single oral dose pharmacoki-
netic interaction study of manidipine and delapril in healthy volunteers. 
Arzneimittelforschung, 53:627–34. 
Suzuki S, Ohtomo M, Ssatoh Y, et al. 1996. Effect of manidipine and 
delapril on insulin sensitivity in type 2diabetic patients with essential 
hypertension. Diab Res Clin Pract, 33: 43–51.
Swales P, Wiliams B. 2002. Calcium channel blockade in combination with 
angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-
receptor) antagonism in hypertensive diabetics and patients with renal 
disease and hypertension. J Renin Aldosterone Syst, 3:79–89.
Taddei S, Virdis A, Ghiadoni L, et al. 2001. Restoration of nitric oxide 
avaibility after calcium antagonist treatment in essential hypertension. 
Hypertension, 37:943–8.
The ALLHAT Ofﬁ  cers and Coordinators for the ALLHAT Collaborative 
Research Group. 2002. Major outcomes in high-risk hypertensive 
patients randomized to angiotensin-converting enzyme inhibitor or 
calcium channel blocker vs diuretic: The Antihypertensive and Lipid-
Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA, 
288:2981–97.
Tojo A, Kimura K, Matsuoka H, et al. 1992. Effects of manidipine hydro-
chloride on the renal microcirculation in spontaneously hypertensive 
rats. J Cardiovasc Pharmacol, 20:895–9.
Trimaco B, Arcucci O, Gacionig G, et al. 2005. Evaluation of different 
combination of antihypertensive drugs in hypertensive patients not 
adequately controlled by previous monotherapy [abstract]. High Blood 
Press Cardiovasc, 12:180(abstract no. 8.5).
[VAC] Veterans Administration Cooperative Study Group on 
Antihypertensive Agents. 1970. Effects of treatment on morbidity in 
hypertension: II results in patients with diastolic blood pressure average 
90 through 114 mm Hg. JAMA, 213:1143–9.
Watanabe H. 2003. Block of T-type calcium channel by dihydropyridine 
calcium antagonists. Teikyo Medical Journal, 26:425–33.
Wolf-Maier K, Cooper RS, Banegas JR, et al. 2003. Hypertension preva-
lence and blood pressure levels in 6 European countries, Canada and 
the United States. JAMA, 289:2363–9.
Zanchetti A, Omboni S, La Commarre P, et al. 2001. Efﬁ  cacy, tolerability, 
and impact on quality of life of long-term treatment with manidipine 
or amlodipine in patients with essential hypertension. J Cardiovasc 
Pharmacol, 38:642–50.
Zanchetti A, Rosei EA, Dal Palu C, et al. 1998. The Verapamil in 
Hypertension and Atherosclerosis Study (VHAS): results of long-term 
randomized treatment with either verapamil or chlorthalidone on carotid 
intima-media thickness. J Hypertens, 16:1667–76.
Zanchetti A, Bond MG, Hennig M, et al. 2002. European Lacidipine Study 
on Atherosclerosis investigators Calcium antagonist lacidipine slows 
down progression of asymptomatic carotid atherosclerosis: principal 
results of the European Lacidipine Study on Atherosclerosis (ELSA), a 
randomized, double-blind, long-term trial. Circulation, 106:2422–7.
Zanchi A, Brunner HR, Waeber B, et al. 1995. Renal hemodynamic and 
protective effects of calcium antagonist in hypertension. J Hypertens, 
13:1363–75.
Zannad F. 2004. Multicentre, randomised, parallel group, double-blind, 
phase III study to compare the antihypertensive effects and tolerability 
of delapril and manidipine monotherapy to delapril plus manidipine 
(CHF 1521 ﬁ  xed combination) in patients with mild to moderate 
 essential hypertension (Data on ﬁ  le). Chiesi Farmaceutici A.p.A. 
Zoppi A, Mugellini A, Preti P, et al. 2003. Effects of the ﬁ  xed combination 
of manidipine plus delapril in the treatment of hypertension inadequately 
controlled by monotherapy with either component: a phase III, multi-
center, open-label, clinical trial. Curr Ther Res, 64:422–33.